Timothy J Mcdonald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8885026/publications.pdf

Version: 2024-02-01

113	5,220	117625	95266
papers	citations	34 h-index	68 g-index

121	121	121	6616
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 190-198.	1.3	7
2	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
3	Mortality amongst children and adolescents with type 1 diabetes in <scp>subâ€Saharan</scp> Africa: The case study of the Changing Diabetes in Children program in Cameroon. Pediatric Diabetes, 2022, 23, 33-37.	2.9	6
4	Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. International Journal of Epidemiology, 2022, 51, 1022-1024.	1.9	7
5	P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure. Journal of Crohn's and Colitis, 2022, 16, i256-i256.	1.3	0
6	OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. Journal of Crohn's and Colitis, 2022, 16, i023-i025.	1.3	1
7	Response to Comment on Meek et al. Reappearance of C-Peptide During the Third Trimester in Type 1 Diabetes Pregnancy: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care 2021;44:1826â€“1834. Diabetes Care, 2022, 45, e43-e44.	8.6	0
8	Type 1 Diabetes Patients With Different Residual Beta-Cell Function but Similar Age, HBA1c, and Cardiorespiratory Fitness Have Differing Exercise-Induced Angiogenic Cell Mobilisation. Frontiers in Endocrinology, 2022, 13, 797438.	3.5	2
9	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
10	Capturing the realâ€world benefit of residual Î²â€cell function during clinically important timeâ€periods in established Type 1 diabetes. Diabetic Medicine, 2022, 39, e14814.	2.3	5
11	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€toâ€thyroxine (<scp>T3</scp>/<scp>T4</scp>) ratio predict therapeutic outcome to <scp>antiâ€TNF</scp> therapies in biologicâ€naÃ¯ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2022, 56, 783-793.	3.7	5
12	Clinical profiles of postâ€load glucose subgroups and their association with glycaemic traits over time: An IMIâ€DIRECT study. Diabetic Medicine, 2021, 38, e14428.	2.3	2
13	Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England. British Journal of Cancer, 2021, 124, 1231-1236.	6.4	41
14	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2021, 25, 1-248.	2.8	7
15	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
16	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
17	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	8.6	52
18	Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?. Diabetes Care, 2021, 44, 1826-1834.	8.6	11

#	Article	IF	Citations
19	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. Diabetes, 2021, 70, 2092-2106.	0.6	17
20	Measurement of Peak C-Peptide at Diagnosis Informs Glycemic Control but not Hypoglycemia in Adults With Type 1 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab127.	0.2	6
21	Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Research and Care, 2021, 9, e002296.	2.8	4
22	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	2.8	5
23	Validating the positivity thresholds of drugâ€tolerant antiâ€infliximab and antiâ€adalimumab antibody assays. Alimentary Pharmacology and Therapeutics, 2021, 53, 128-137.	3.7	9
24	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
25	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	8.6	16
26	Predictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS Study. Diabetes Care, 2020, 43, 44-52.	8.6	18
27	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohnâ€™s Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
28	Type 1 diabetes can present before the age of 6Âmonths and is characterised by autoimmunity and rapid loss of beta cells. Diabetologia, 2020, 63, 2605-2615.	6.3	24
29	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	8.2	8
30	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	6.1	3
31	Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual Î²-Cell Function. Diabetes Care, 2020, 43, 2362-2370.	8.6	11
32	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood, 2020, 105, 957-963.	1.9	4
33	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	8.4	47
34	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia, 2020, 63, 1258-1267.	6.3	98
35	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	2.3	5
36	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. Diabetologia, 2020, 63, 744-756.	6.3	12

#	Article	IF	Citations
37	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	1.9	8
38	Parental experiences of a diagnosis of neonatal diabetes and perceptions of newborn screening for glucose: a qualitative study. BMJ Open, 2020, 10, e037312.	1.9	2
39	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. PLoS ONE, 2020, 15, e0242360.	2.5	7
40	Title is missing!. , 2020, 17, e1003149.		0
41	Title is missing!. , 2020, 17, e1003149.		0
42	Title is missing!. , 2020, 17, e1003149.		0
43	Title is missing!. , 2020, 17, e1003149.		0
44	Title is missing!. , 2020, 17, e1003149.		0
45	Type 1 diabetes genetic risk score discriminates between monogenic and Type 1 diabetes in children diagnosed at the age of <5 years in the Iranian population. Diabetic Medicine, 2019, 36, 1694-1702.	2.3	13
46	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	5.5	43
47	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2019, 62, 1601-1615.	6.3	22
48	Stability of urinary albumin and creatinine after 12 months storage at â˜'20â€˜Â°C and â˜'80â€˜Â°C. Practical Laboratory Medicine, 2019, 15, e00120.	1.3	8
49	The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis. Metabolism: Clinical and Experimental, 2019, 95, 1-7.	3.4	6
50	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
51	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA‹sub›1c‹/sub› in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
52	Type 1 diabetes defined by severe insulin deficiency occurs after 30Âyears of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	6.3	100
53	Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways. BMJ Open Diabetes Research and Care, 2019, 7, e000721.	2.8	9
54	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	8.6	19

#	Article	IF	Citations
55	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibodyâ€“Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
56	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1103-1116.	3.7	31
57	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
58	A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes. Diabetologia, 2018, 61, 862-869.	6.3	33
59	Comment on: â€œDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â^'4 and â^'5 trialsâ€• Diabetes, Obesity and Metabolism, 2018, 20, 1549-1550.	4.4	1
60	A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells. Free Radical Biology and Medicine, 2018, 120, 246-254.	2.9	20
61	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
62	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sciences, Society and Policy, 2018, 14, 20.	3.2	7
63	Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1Î²-associated renal disease and can be symptomatic. CKJ: Clinical Kidney Journal, 2018, 11, 453-458.	2.9	10
64	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	8.6	81
65	Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clinical Medicine, 2017, 17, 18-21.	1.9	13
66	Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. Diabetologia, 2017, 60, 2168-2173.	6.3	12
67	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	8.6	111
68	Proinsulin is stable at room temperature for 24 hours in EDTA: A clinical laboratory analysis (adAPT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	2
69	Markers of Î²-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	8.6	132
70	Random nonâ€fasting Câ€“peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	2.3	50
71	Low IgE Is a Useful Tool to Identify STAT3 Gain-of-Function Mutations. Clinical Chemistry, 2016, 62, 1536-1538.	3.2	5
72	Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function. Methods in Molecular Biology, 2016, 1433, 93-102.	0.9	7

#	Article	IF	Citations
73	Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes and Metabolism, 2016, 42, 453-456.	2.9	10
74	A cautionary tale: Unforeseen consequences of lean processing in a blood sciences laboratory. Clinical Biochemistry, 2016, 49, 1311-1312.	1.9	0
75	Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia, 2016, 59, 2722-2726.	6.3	37
76	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	8.6	172
77	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	8.6	231
78	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	8.6	104
79	Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Annals of Clinical Biochemistry, 2015, 52, 672-674.	1.6	6
80	Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. Clinical Biochemistry, 2015, 48, 1354-1357.	1.9	55
81	Investigating hyperkalaemia in adults. BMJ, The, 2015, 351, h4762.	6.0	13
82	Diagnostic Confusion? Repeat HbA1cfor the Diagnosis of Diabetes: Figure 1. Diabetes Care, 2014, 37, e135-e136.	8.6	11
83	Effect of the Holiday Season in Patients With Diabetes: Glycemia and Lipids Increase Postholiday, but the Effect Is Small and Transient. Diabetes Care, 2014, 37, e98-e99.	8.6	9
84	TheHNF4AR76W mutation causes atypical dominant Fanconi syndrome in addition to a Î² cell phenotype. Journal of Medical Genetics, 2014, 51, 165-169.	3.2	82
85	Home Urine C-Peptide Creatinine Ratio Can Be Used to Monitor Islet Transplant Function: Figure 1. Diabetes Care, 2014, 37, 1737-1740.	8.6	5
86	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	6.3	240
87	The association between postprandial urinary Câ€peptide creatinine ratio and the treatment response to liraglutide: a multiâ€centre observational study. Diabetic Medicine, 2014, 31, 403-411.	2.3	18
88	Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother With KCNJ11-Related Neonatal Diabetes. Diabetes Care, 2014, 37, 3333-3335.	8.6	19
89	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Genetics, 2014, 46, 812-814.	21.4	411
90	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2014, 57, 1132-1142.	6.3	48

#	Article	IF	Citations
91	Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia, 2013, 56, 218-221.	6.3	24
92	Cystatin C is not a good candidate biomarker for HNF1A-MODY. Acta Diabetologica, 2013, 50, 815-820.	2.5	8
93	Maturity onset diabetes of the young: identification and diagnosis. Annals of Clinical Biochemistry, 2013, 50, 403-415.	1.6	131
94	Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open, 2013, 3, e003193.	1.9	17
95	Preanalytical sample handling of venous blood: how to ensure your glucose measurement is accurate and reliable. Practical Diabetes, 2013, 30, 128-131.	0.3	5
96	Urinary Câ€peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 2013, 30, 1342-1348.	2.3	13
97	The impact of gender on urine C-peptide creatinine ratio interpretation. Annals of Clinical Biochemistry, 2012, 49, 363-368.	1.6	17
98	The impact of insulin administration during the mixed meal tolerance test. Diabetic Medicine, 2012, 29, 1279-1284.	2.3	19
99	Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatric Diabetes, 2012, 14, n/a-n/a.	2.9	29
100	Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and Type 2 diabetes. Clinica Chimica Acta, 2012, 413, 927-932.	1.1	39
101	Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 2012, 12, 6.	2.2	14
102	EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room Temperature. PLoS ONE, 2012, 7, e42084.	2.5	39
103	The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 2012, 55, 1265-1272.	6.3	238
104	Validation of a singleâ€sample urinary Câ€peptide creatinine ratio as a reproducible alternative to serum Câ€peptide in patients with Type 2 diabetes. Diabetic Medicine, 2012, 29, 90-93.	2.3	29
105	Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. BMJ Case Reports, 2012, 2012, bcr0120125612-bcr0120125612.	0.5	2
106	Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-Î±/Hepatocyte Nuclear Factor 4-Î± Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes. Diabetes Care, 2011, 34, 286-291.	8.6	123
107	High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care, 2011, 34, 1860-1862.	8.6	90
108	A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 2011, 412, 1999-2001.	1.1	2

#	Article	IF	Citations
109	Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860-1862. Diabetes Care, 2011, 34, e187-e187.	8.6	0
110	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	2.3	32
111	Islet autoantibodies can discriminate maturityâ€onset diabetes of the young (MODY) from Typeâ€ƒ1 diabetes. Diabetic Medicine, 2011, 28, 1028-1033.	2.3	173
112	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	8.6	62
113	Stability and Reproducibility of a Single-Sample Urinary C-Peptide/Creatinine Ratio and Its Correlation with 24-h Urinary C-Peptide. Clinical Chemistry, 2009, 55, 2035-2039.	3.2	60